C
Charles H. Redfern
Researcher at Sharp HealthCare
Publications - 47
Citations - 7943
Charles H. Redfern is an academic researcher from Sharp HealthCare. The author has contributed to research in topics: Prostate cancer & Trastuzumab. The author has an hindex of 18, co-authored 44 publications receiving 6766 citations. Previous affiliations of Charles H. Redfern include Sharp Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W. Kantoff,Celestia S. Higano,N. Shore,E. Roy Berger,Eric J. Small,David F. Penson,Charles H. Redfern,Anna C. Ferrari,Robert Dreicer,Robert B. Sims,Yi Xu,Mark W. Frohlich,Paul F. Schellhammer +12 more
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Journal ArticleDOI
Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
Eric J. Small,Paul F. Schellhammer,Celestia S. Higano,Charles H. Redfern,John Nemunaitis,Frank H. Valone,Suleman S. Verjee,Lori A. Jones,Robert M. Hershberg +8 more
TL;DR: It is suggested that sipuleucel-T may provide a survival advantage to asymptomatic HRPC patients in a phase III study and was well tolerated.
Journal ArticleDOI
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi,Haeseong Park,Rashmi Krishna Murthy,Hiroji Iwata,Kenji Tamura,Junji Tsurutani,Alvaro Moreno-Aspitia,Toshihiko Doi,Yasuaki Sagara,Charles H. Redfern,Ian E. Krop,Caleb Lee,Yoshihiko Fujisaki,Masahiro Sugihara,Lin Zhang,Javad Shahidi,Shunji Takahashi +16 more
TL;DR: The novel Her2-targeted ADC, T-DXd, demonstrated promising preliminary antitumor activity in patients with HER2-low breast cancer and should be monitored closely and proactively managed.
Journal ArticleDOI
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Tomasz M. Beer,Christopher W. Ryan,Peter Venner,Daniel P. Petrylak,Gurkamal Chatta,J. Dean Ruether,Charles H. Redfern,Louis Fehrenbacher,Mansoor N. Saleh,David M. Waterhouse,Michael A. Carducci,Daniel Vicario,Robert Dreicer,Celestia S. Higano,Frederick R. Ahmann,Kim N. Chi,W. David Henner,Alan Arroyo,Fong Clow +18 more
TL;DR: DN-101 treatment was associated with improved survival, but this will require confirmation because survival was not a primary end point, and the addition of weekly DN-101 did not increase the toxicity of weekly docetaxel.
Journal ArticleDOI
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Noel W. Clarke,Paweł Wiechno,Boris Alekseev,Nuria Sala,Robert H. Jones,Ivo Kocak,Vincenzo Emanuele Chiuri,Jacek Jassem,Aude Flechon,Charles H. Redfern,C. Goessl,Joseph Burgents,Robert Kozarski,Darren Hodgson,Maria Learoyd,Fred Saad +15 more
TL;DR: Olaparib in combination with abiraterone provided clinical efficacy benefit for patients with metastatic castration-resistant prostate cancer and preclinical data suggest synergy between olaparIB and androgen pathway inhibitors.